
MÃ-riam Mañosa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6726714/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry. Journal of Clinical Medicine, 2022, 11, 421.	1.0	8
2	Treatment Adherence and Clinical Outcomes of Patients with Inflammatory Bowel Disease on Biological Agents During the SARS-CoV-2 Pandemic. Digestive Diseases and Sciences, 2021, 66, 4191-4196.	1.1	12
3	Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry. Journal of Crohn's and Colitis, 2021, 15, 1846-1851.	0.6	39
4	Clinical outcome after antiâ€ŧumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS longâ€ŧerm study. Alimentary Pharmacology and Therapeutics, 2021, 53, 1277-1288.	1.9	16
5	Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease. Aging Clinical and Experimental Research, 2021, 33, 2355-2359.	1.4	6
6	Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease. Drugs and Aging, 2021, 38, 193-203.	1.3	2
7	Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry. Journal of Crohn's and Colitis, 2021, , .	0.6	6
8	A novel distinctive form of identification for differential diagnosis of irritable bowel syndrome, inflammatory bowel disease, and healthy controls. GastroHep, 2020, 2, 193-204.	0.3	3
9	Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry. Journal of Crohn's and Colitis, 2020, 14, 1290-1298.	0.6	5
10	Increased risk of thiopurineâ€related adverse events in elderly patients with IBD. Alimentary Pharmacology and Therapeutics, 2019, 50, 780-788.	1.9	40
11	Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry. Inflammatory Bowel Diseases, 2019, 25, 1862-1870.	0.9	28
12	Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers. American Journal of Gastroenterology, 2019, 114, 771-776.	0.2	9
13	Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. Journal of Crohn's and Colitis, 2018, 12, 687-694.	0.6	10
14	Letter: phenotype and natural history of elderly onset inflammatory bowel disease—Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1421-1422.	1.9	2
15	Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, caseâ€control study. Alimentary Pharmacology and Therapeutics, 2018, 47, 605-614.	1.9	57
16	OP034 The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry. Journal of Crohn's and Colitis, 2018, 12, S023-S025.	0.6	4
17	Short and longâ€ŧerm effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. Alimentary Pharmacology and Therapeutics, 2018, 48, 839-851.	1.9	71
18	Review article: the relationship between obesity, bariatric surgery, and inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 807-816.	1.9	24

MÃRIAM MAñOSA

#	Article	IF	CITATIONS
19	Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. American Journal of Gastroenterology, 2017, 112, 120-131.	0.2	93
20	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la monitorizaciÃ3n, prevenciÃ3n y tratamiento de la recurrencia posquirúrgica en la enfermedad de Crohn. GastroenterologÃa Y HepatologÃa, 2017, 40, 472-483.	0.2	27
21	Editorial: therapeutic drug monitoring for antiâ€ <scp>TNF</scp> agents—has it all been said?. Alimentary Pharmacology and Therapeutics, 2017, 46, 1113-1114.	1.9	1
22	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the monitoring, prevention and treatment of post-operative recurrence in Crohn's disease. GastroenterologAa Y HepatologÃa (English Edition), 2017, 40, 472-483.	0.0	4
23	Fecal Calprotectin Levels Are Closely Correlated with the Absence of Relevant Mucosal Lesions in Postoperative Crohn' s Disease. Inflammatory Bowel Diseases, 2016, 22, 2879-2885.	0.9	33
24	Improved outcome of acute severe ulcerative colitis while using early predictors of corticosteroid failure and rescue therapies. Digestive and Liver Disease, 2016, 48, 608-612.	0.4	17
25	Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment. Journal of Crohn's and Colitis, 2016, 10, 1186-1193.	0.6	33
26	Addition of mesalazine for subclinical postâ€surgical endoscopic recurrence of <scp>C</scp> rohn's disease despite preventive thiopurine therapy: A case–control study. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1413-1417.	1.4	7
27	Long-term Comparative Efficacy of Cyclosporine- or Infliximab-based Strategies for the Management of Steroid-refractory Ulcerative Colitis Attacks. Inflammatory Bowel Diseases, 2014, 20, 1375-1381.	0.9	24
28	Intravenous corticosteroids in moderately active ulcerative colitis refractory to oral corticosteroids. Journal of Crohn's and Colitis, 2014, 8, 1523-1528.	0.6	17
29	Optimizing post-operative Crohn's disease treatment. Annals of Gastroenterology, 2014, 27, 313-319.	0.4	9
30	Fecundity, pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease: a large cohort survey. Scandinavian Journal of Gastroenterology, 2013, 48, 427-432.	0.6	72
31	Current incidence of active tuberculosis in IBD patients treated with anti-TNF agents: Still room for improvement. Journal of Crohn's and Colitis, 2013, 7, e499-e500.	0.6	13
32	Addition of Metronidazole to Azathioprine for the Prevention of Postoperative Recurrence of Crohn's Disease. Inflammatory Bowel Diseases, 2013, 19, 1.	0.9	51
33	Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. Digestive and Liver Disease, 2012, 44, 206-210.	0.4	41
34	Methotrexate in ulcerative colitis: A Spanish multicentric study on clinical use and efficacy. Journal of Crohn's and Colitis, 2011, 5, 397-401.	0.6	25
35	Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose "Escalation―in Patients Losing Response. Journal of Clinical Gastroenterology, 2011, 45, 113-118.	1.1	114
36	Decision tree for early introduction of rescue therapy in active ulcerative colitis treated with steroids. Inflammatory Bowel Diseases, 2011, 17, 2497-2502.	0.9	25

#	Article	IF	CITATIONS
37	Impact of azathioprine on the prevention of postoperative Crohn's disease recurrence: Results of a prospective, observational, long-term follow-up study. Inflammatory Bowel Diseases, 2008, 14, 508-513.	0.9	91
38	Predictors of Clinical Response to Systemic Steroids in Active Ulcerative Colitis. Digestive Diseases and Sciences, 2006, 51, 1434-1438.	1.1	27